NCT02558374View on ClinicalTrials.gov

Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

708

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Open-angle GlaucomaOcular Hypertension
Interventions
DRUG

AR-13324 Ophthalmic Solution 0.02%

1 drop once daily (QD), PM, OU

DRUG

Timolol Maleate Ophthalmic Solution 0.5% BID

1 drop BID, AM/PM, OU

OTHER

Placebo

1 drop QD, AM, OU

Trial Locations (1)

07921

Aerie Pharmaceuticals, Bedminster

Sponsors
All Listed Sponsors
lead

Aerie Pharmaceuticals

INDUSTRY

NCT02558374 - Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension | Biotech Hunter | Biotech Hunter